APRE News and Press, Aprea Therapeutics Inc. From 03/15/22

BOSTON, March 15, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today reported financial results for the three m...

BOSTON, Jan. 06, 2022 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that Christian S. Schad...

BOSTON, Dec. 14, 2021 (GLOBE NEWSWIRE) -- Lead investigators from clinical trials evaluating eprenetapopt in patients with TP53 mutant MDS or AML presented positive, updated data at the 2021 ASH Annual Meeting. All studies evaluated the tolerability and efficacy of Aprea Therap...

60% relapse free survival at 1 year post-transplant 79% overall survival at 1 year post-transplant Median overall survival of 20.6 months BOSTON, Dec. 13, 2021 (GLOBE NEWSWIRE) --  Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on develop...

4 Penny Stocks Under $5 to Watch in December 2021 Making a list of the best penny stocks to buy in December? Well, there are plenty of options to choose from. The first step as an investor is to understand what type of trader you are and what your tolerance for risk is. On one hand, we ...

Ensysce Biosciences (NASDAQ:ENSC) +83%. Inspira Technologies (NASDAQ:IINN) +59%. American Virtual Cloud Technologies (NASDAQ:AVCT) +29% announces significant projected revenue growth of Kandy, its cloud communications platform. Siyata Mobile (NASDAQ:SYTA) +28%. Digital Brands (NASDAQ:DBG...

A group of tiny healthcare stocks has risen sharply in the pre-market as investor chatter on the stocks gained momentum on social media. Inspira Technologies (NASDAQ:IINN), a nano-cap stock, has added ~49.8% on above-average volume. About 5.1M of Inspira (IINN) shares have changed hands ...

Aprea Therapeutics (NASDAQ:APRE) announces that the FDA has removed the full clinical hold on the Company’s trial evaluating the combination of eprenetapopt with acalabrutinib or with venetoclax and rituximab in lymphoid malignancies. Shares up 9.2% premarket at $4.50. ȁ...

BOSTON, Dec. 09, 2021 (GLOBE NEWSWIRE) -- Aprea Therapeutics, Inc. (Nasdaq: APRE), a biopharmaceutical company focused on developing and commercializing novel cancer therapeutics that reactivate the mutant tumor suppressor protein, p53, today announced that the U.S. Food and Drug Admin...

Aprea Therapeutics (NASDAQ:APRE): Q3 GAAP EPS of -$0.45 beats by $0.01. Cash and cash equivalents of $61.42M. Press Release For further details see: Aprea Therapeutics EPS beats by $0.01